Patient Safety Information
Breast Implants
Sientra’s Silicone Gel Breast Implants are indicated for breast augmentation in women at least 22 years old and for breast reconstruction. Breast augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the result of primary breast augmentation surgery. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the results of a primary breast reconstruction surgery. Breast implant surgery is contraindicated in women with active infection anywhere in their bodies, with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions and, who are pregnant or nursing.
Key complications include capsular contracture, implant removal, rupture and reoperation. For more detailed information about the risks and benefits of Sientra breast implants, please visit www.sientra.com/resources or call Sientra at (888) 708-0808. If you have a problem with your breast implant(s), tell your doctor immediately. In addition to informing your doctor, you can report a problem to Sientra at (888) 708-0808. Sientra breast implants with High-Strength silicone gel are only available through board-certified or board-eligible plastic surgeons.
Scar Treatment
BIOCORNEUM is for external use only. Avoid direct contact with eyes, mucous membranes, third degree burns, and open wounds. BIOCORNEUM should not be used on damaged or broken skin. If irritation occurs, discontinue use and consult your physician. Keep this product out of reach of children. This product has not been shown to help prevent skin cancer or early skin aging.
https://sientra.com/commitment-to-safety/
Breast Implants
Sientra’s Silicone Gel Breast Implants are indicated for breast augmentation in women at least 22 years old and for breast reconstruction. Breast augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the result of primary breast augmentation surgery. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the results of a primary breast reconstruction surgery. Breast implant surgery is contraindicated in women with active infection anywhere in their bodies, with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions and, who are pregnant or nursing.
Key complications include capsular contracture, implant removal, rupture and reoperation. For more detailed information about the risks and benefits of Sientra breast implants, please visit www.sientra.com/resources or call Sientra at (888) 708-0808. If you have a problem with your breast implant(s), tell your doctor immediately. In addition to informing your doctor, you can report a problem to Sientra at (888) 708-0808. Sientra breast implants with High-Strength silicone gel are only available through board-certified or board-eligible plastic surgeons.
Scar Treatment
BIOCORNEUM is for external use only. Avoid direct contact with eyes, mucous membranes, third degree burns, and open wounds. BIOCORNEUM should not be used on damaged or broken skin. If irritation occurs, discontinue use and consult your physician. Keep this product out of reach of children. This product has not been shown to help prevent skin cancer or early skin aging.
https://sientra.com/commitment-to-safety/
Location: United States, California, Santa Barbara
Employees: 201-500
Phone: +1 805-562-3500
Total raised: $65M
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Abingworth... | abingworth... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.03.2012 | Series C | $65M | - |
Mentions in press and media 11
| Date | Title | Description |
| 24.06.2024 | Tiger Aesthetics™ and Mission Plasticos Renew Partnership to Continue Nationwide Reconstructive Surgery Program | 5-Year Commitment will Continue Reshaping Lives: Full Circle™ - A Philanthropic Initiative for Women Without Access to Reconstructive Care in America FRANKLIN, WISCONSIN, UNITED STATES, June 24, 2024 /EINPresswire.com/ -- Tiger Aesthetics, ... |
| 18.04.2024 | Nuance Medical Completes Acquisition of BIOCORNEUM Scar Treatment Brand, to Become a Part of the Biodermis Portfolio | BIOCORNEUM is a state-of-the-art silicone gel scar treatment brand,. Nuance Medical completed the acquisition of BIOCORNEUM, a state-of-the-art silicone gel scar treatment brand, previously owned by Sientra. Effective immediately, BIOCORNEU... |
| 21.10.2022 | Sientra Announces Pricing of $13.2 Million Public Offering | SANTA BARBARA, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced the pricing... |
| 21.09.2021 | Mission Plasticos : Announces Launch Of Reshaping Lives America Funded By $1 Million Donation From Sientra | ORANGE COUNTY, Calif., Sept. 21, 2021 /PRNewswire/ -- Mission Plasticos, a 501-c3 non-profit organization dedicated to providing reconstructive surgical care to those in medically underserved communities around the globe, today announced th... |
| 04.11.2014 | Sientra nets $80m in IPO | Breast implant maker Sientra (NSDQ:SIEN) said today that the proceeds from its initial public offering, which closed yesterday, put $80.2 million into its coffers. Sientra floated 5.75 million shares at $15 apiece for total proceeds of near... |
| 30.10.2014 | Sientra Raised $75m in IPO | Sientra, Inc. (NASDAQ: SIEN), a Santa Barbara-based medical aesthetics company, raised $75m for its Initial Public Offering after pricing its 5 million shares at $15 per share. The stock began trading Wednesday 29th on the NASDAQ under the ... |
| 29.10.2014 | Sientra prices $75m IPO | Breast implant maker Sientra priced its initial public offering at $15 per share, saying it plans to issue 5 million shares for a total of $75 million. Sientra, which also has designed implants for the buttocks, calf, pectoral region and fa... |
| 23.09.2014 | Breast implant maker Sientra registers an $86M IPO | California medical device maker Sientra Inc. is looking to hit the public markets with an initial public offering that could raise as much as $86.3 million, according to an SEC filing. The company has not yet released the number of shares i... |
| 29.03.2012 | Sientra Closes $65M Series C Financing | Sientra, a Santa Barbara, CA-based medical device company focused on the aesthetic and plastic surgery markets, has closed a $65m Series C financing. The round was led by Abingworth, with participation by Clarus Ventures, OrbiMed Advisors a... |
| 28.03.2012 | Sientra Gains $65M | Santa Barbara-based Sientra, a developer of FDA-approved, silicone breast implants, said Wednesday that it has raised $65M in a Series C funding round. The funding was led by Abingworth, and also included Clarus Ventures, OrbiMed Advisors, ... |
Show more